LionBird

LionBird is a venture capital firm investing in early-stage technology startups that improve offline processes in healthcare, commerce, and enterprise sectors. Founded in 2012, the firm operates from offices in Tel Aviv, Israel, and Evanston, Illinois, USA. LionBird focuses on pre-scale digital health companies, providing capital and operational support to mission-driven teams aiming to redefine the human-technology relationship in healthcare. The firm's portfolio includes over 30 companies, such as Tyto Care, Ovia Health, C2i Genomics, Assured Allies, Protenus, Kit Check, Theranica, Laguna Health, and Rhino Health. In April 2022, LionBird closed its third fund, LionBird III, with $85 million, supported by institutional investors like the Healthcare of Ontario Pension Plan (HOOPP) and industry executives. The fund aims to invest in 15 to 20 early-stage digital health companies, continuing LionBird's commitment to supporting innovative solutions in the healthcare sector. The firm's investment strategy centers on leveraging online technologies to transform traditional offline business processes, particularly in healthcare, commerce, and enterprise domains. LionBird's team comprises experienced professionals with backgrounds in software and healthcare industries, enabling them to provide both capital and strategic guidance to their portfolio companies. The firm's approach emphasizes a 'co-founder' mentality, working closely with entrepreneurs to drive growth and success. LionBird's track record includes notable exits such as Ovia Health, C2i Genomics, and Protenus, reflecting its effective investment strategy and value-added support to portfolio companies. The firm's philosophy combines real-life business understanding with a collaborative approach, aiming to foster innovation and growth in the sectors it invests in.

LionBird's commitment to the digital health sector is evident in its dedicated fund, LionBird III, which focuses exclusively on early-stage digital health investments. The fund's closing in April 2022 marked a significant milestone, with plans to invest in a diverse range of companies within the digital health space. The firm's expansion of its investment team with new partners, such as Robert Lord and Gal Noyman-Veksler, underscores its dedication to enhancing its support for portfolio companies. LionBird's strategic focus on digital health aligns with its mission to support innovative solutions that address challenges in the healthcare industry. The firm's approach combines financial investment with operational support, aiming to accelerate the growth and impact of its portfolio companies. LionBird's active involvement in the digital health ecosystem reflects its commitment to fostering innovation and improving healthcare delivery through technology.

The firm's portfolio showcases a range of companies that exemplify its investment philosophy. Tyto Care, for instance, brings the traditional doctor's physical exam to the home, aligning with LionBird's focus on innovative healthcare solutions. Ovia Health, acquired by LabCorp, represents a successful exit, highlighting the firm's ability to identify and support companies with significant growth potential. C2i Genomics and Protenus are other examples of LionBird's investments in companies that are redefining their respective industries. The firm's diverse portfolio reflects its strategic focus on sectors where technology can drive substantial improvements in efficiency and effectiveness. LionBird's ongoing support for its portfolio companies demonstrates its commitment to fostering long-term success and innovation in the sectors it targets.